Stockreport
Top Pictet Fund Manager Sees Biotech Stocks Joining AI-Euphoria [BNN Bloomberg (Canada)]
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
The biotech sector is showing significant catch-up potential, after missing out on the investor euphoria that's driven AI stocks to new heights in recent months, said Hans Peter Portner, who manages Banque Pictet & Cie's largest fund, Global Megatrend Selection. “We are ahead of a massive wave of new innovation in general, but in particular within biotech due to AI,” Portner said in an interview in Geneva. He said he expects Pictet's biotech-focused fund to double in size in the next three years. The firm's broader Global Megatrend Selection fund has about $13.4 billion in assets under management. It has gained about 23% in the past year, compared to a 32% increase in the S&P 500. The fund has outperformed about 75% of peers, according to data compiled by Bloomberg. The use of AI in biotechs is widespread, with several companies acquired or partnered up with machine learning firms whose products can speed up and simplify R&D but also sort data much faster. AI is also used by so
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | GILD | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GILD alerts
GILD alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
NEWS
NEWS
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Morgan Stanley from $80.00 to $78.00. They now have an "equal weight" rating on the stock.[MarketBeat]
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at TD Cowen from $90.00 to $85.00. They now have a "buy" rating on the stock.[MarketBeat]
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Royal Bank of Canada from $76.00 to $74.00. They now have a "sector perform" rating on the stock.[MarketBeat]
- Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat [Yahoo! Finance][Yahoo! Finance]
- Merus (MRUS) Moves 7.1% Higher: Will This Strength Last? [Yahoo! Finance][Yahoo! Finance]
- More
GILD
SEC Filings
SEC Filings
- 4/26/24 - Form 4
- 4/25/24 - Form 8-K
- 4/2/24 - Form 4
- GILD's page on the SEC website
- More